Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 2/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3311939 | 0.91 | KMT2A (0.41) | MEN1KMT2AALDH1A1NPC1POLB | |
| SCHEMBL3316213 | 0.78 | — | — | |
| SCHEMBL3312702 | 0.64 | ALDH1A1 (0.35) | MEN1KMT2AALDH1A1SLC6A4FAAH | |
| SCHEMBL18123010 | 0.64 | HTR2C (0.43) | MEN1KMT2AALDH1A1NPC1POLB | |
| SCHEMBL4748057 | 0.63 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1FAAHCNR2 | |
| SCHEMBL15300707 | 0.62 | PRKAB2 (0.42) | MEN1KMT2AALDH1A1CNR2LPAR1 | |
| SCHEMBL15300908 | 0.62 | PRKAB2 (0.42) | MEN1KMT2AALDH1A1CNR2LPAR1 | |
| SCHEMBL15300706 | 0.62 | PRKAB2 (0.42) | MEN1KMT2AALDH1A1CNR2LPAR1 | |
| SCHEMBL3311930 | 0.62 | ALDH1A1 (0.38) | MEN1KMT2AALDH1A1SLC6A4 | |
| SCHEMBL1930627 | 0.62 | TSHR (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113816-A1 | METHOD FOR PREPARTION OF SUBSTITUTED ADAMANTYLARYMAGNESIUM HALIDES | JSC GRINDEKS (LV) | 2010-05-06 | — | — | US | disclosed |
| EP-2129679-A2 | A METHOD FOR PREPARATION OF SUBSTITUTED ADAMANTYLARYLMAGNESIUM HALIDES | Grindeks, a joint stock company (LV) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008080993-A2 | A METHOD FOR PREPARATION OF SUBSTITUTED ADAMANTYLARYLMAGNESIUM HALIDES | KALVINSH IVARS (LV) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113816-A1 | METHOD FOR PREPARTION OF SUBSTITUTED ADAMANTYLARYMAGNESIUM HALIDES | AGL, MACROD1, MACROD2 | MEN1 294/4885KMT2A 1169/4885ALDH1A1 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.